That was part reason for my post above concerning my thinking -...

That was part reason for my post above concerning my thinking - I just don't understand it either. The only thing I can come up with is that the market doesn't believe in BOT's numbers or potential sales. I think that may be influenced by Qbrexza only earning $25m last year, but SB is a superior product which will benefit from being newly introduced and BOT do seem to present a convincing sales and distribution plan. That and the actual evidence of sales numbers in Japan would indicate its potential to be a decent success.